Pompe disease is a rare genetic condition where the body can’t properly break down a stored sugar called glycogen inside cells. This buildup damages muscles throughout the body, causing progressive weakness that affects movement, breathing, and in infants, the heart. It occurs in roughly 2 out of every 100,000 live births and ranges from a severe infantile form to a slower adult form that can go undiagnosed for a decade or more.
How Pompe Disease Damages Muscles
Every cell in your body contains tiny recycling centers called lysosomes. Inside these structures, an enzyme breaks down glycogen (a stored form of sugar) into glucose your cells can use for energy. In Pompe disease, mutations in the GAA gene mean this enzyme either doesn’t work well or is almost entirely absent. Glycogen accumulates to toxic levels inside lysosomes, progressively damaging organs and tissues, with skeletal muscles and the diaphragm taking the hardest hit.
The amount of working enzyme you produce determines how severe the disease is and when symptoms appear. Infants with almost no enzyme activity develop life-threatening symptoms within months. People who retain a small amount of enzyme function may not notice anything wrong until their 30s, 40s, or later.
Infantile-Onset Symptoms
The infantile form, called IOPD, appears before 12 months of age and is the most severe. Babies develop an enlarged, thickened heart muscle that can lead to heart failure. They show profound “floppiness” (low muscle tone), struggle to breathe on their own, and have difficulty feeding. An enlarged tongue and enlarged liver are common. Without treatment, the classic form historically led to death from heart and lung failure within the first year of life.
These symptoms can be deceptively nonspecific early on. One documented case involved a 4-month-old brought to medical attention only for poor weight gain and a persistent cough. Because the early signs overlap with many other infant conditions, diagnosis is sometimes delayed even in this severe form. Pompe disease is now included on the federally recommended newborn screening panel in the United States, which allows earlier detection through a simple blood test at birth.
Late-Onset Symptoms in Children and Adults
Late-onset Pompe disease (LOPD) can begin any time after the first year of life, though many people aren’t diagnosed until adulthood. The average delay between first symptoms and a confirmed diagnosis is about 10 years. Unlike the infantile form, LOPD typically does not affect the heart. Instead, it centers on progressive weakness in the muscles closest to the trunk of the body and the muscles used for breathing.
Muscle Weakness and Mobility Problems
The earliest signs are often subtle: unusual fatigue during exercise, muscle pain, or a vague sense that physical tasks are getting harder. Over time, weakness concentrates in the hip and shoulder girdle muscles and the muscles along the spine. This pattern makes it increasingly difficult to climb stairs, rise from a chair, or lift your arms overhead. Nearly 80% of adults with LOPD develop noticeable changes in how they walk.
The characteristic gait is often described as waddling. This happens because weakened hip muscles can’t stabilize the pelvis during each step, causing the opposite side to drop. Research comparing adults with LOPD to healthy controls found they walked significantly slower (roughly 0.87 meters per second versus 1.24) and covered far less distance in a standard six-minute walk test (about 380 meters versus 544). Recurrent falls are common. In one study of patients, 24% used a walking aid and 17% needed regular mobility assistance.
Breathing Difficulty
Respiratory problems are a defining feature of LOPD and can sometimes appear before noticeable limb weakness. Glycogen accumulation in respiratory muscles, particularly the diaphragm, reduces their ability to contract. Because the diaphragm does most of the work of breathing, its weakness has outsized consequences. Lung function measured while lying down drops by more than 25% compared to sitting upright, a hallmark finding in Pompe disease.
Diaphragm weakness first shows up at night. When you lie flat, gravity no longer helps the diaphragm move, so breathing becomes shallow. This nocturnal underbreathing disrupts sleep and leads to a cluster of recognizable symptoms: morning headaches, excessive daytime sleepiness, and unrefreshing sleep. Over time, the ability to cough effectively weakens too, raising the risk of chest infections. In one patient cohort, 38% required breathing support (typically a mask-based ventilator used at night). Breathing muscle strength tends to decline by 3 to 4% per year without treatment.
Other Symptoms
Elevated levels of a muscle enzyme called CK in routine blood work can be an early clue, sometimes appearing before any obvious weakness. Tongue enlargement from glycogen buildup occurs in many LOPD patients and can be present even when facial muscles are unaffected. Some people also experience difficulty swallowing as the disease progresses.
Why Pompe Disease Is Often Misdiagnosed
The slow, nonspecific onset of LOPD means it frequently masquerades as other conditions. Limb-girdle muscular dystrophy is the most common misdiagnosis, but patients have also been told they have inflammatory muscle disease, other inherited myopathies, nerve disorders, or even functional (non-organic) weakness. In screening studies of patients suspected of having Pompe disease, those who tested negative carried diagnoses spanning at least a dozen different neuromuscular conditions.
A key distinguishing feature is the combination of proximal limb weakness with diaphragm involvement out of proportion to overall muscle weakness. If you have unexplained muscle weakness along with sleep-related breathing symptoms or a drop in lung capacity when lying down, Pompe disease is worth investigating. Diagnosis starts with a simple blood test measuring the activity of the missing enzyme, often performed on a dried blood spot. Normal enzyme activity is generally above 15% of the daily mean; people with Pompe disease fall well below that threshold. Genetic testing confirms the diagnosis.
How Symptoms Are Managed
Enzyme replacement therapy (ERT) is the primary treatment for both forms of Pompe disease. It delivers a manufactured version of the missing enzyme through regular infusions. For infants, early treatment can prevent or reduce heart damage and improve survival dramatically compared to the natural course of the disease. For adults, ERT helps stabilize or slow the decline in muscle and lung function, though it does not reverse damage already done.
Respiratory support, usually a bilevel positive airway pressure (BiPAP) machine worn during sleep, is a cornerstone of managing breathing symptoms in LOPD. Physical therapy focused on maintaining strength and flexibility plays an important ongoing role, and regular monitoring of lung function helps guide treatment decisions as the disease progresses.